Association between Adora2A rs2298383 polymorphism and Parkinson’s disease in a Greek population

Vasiliki Karpa, Kallirhoe Kalinderi, Anthi Chatzikyriakidou, Charalambos Karakasis, Theodore Lialiaris, Sevasti Bostanjopoulou, Liana Fidani


Parkinson’s Disease (PD) is a serious neurodegenerative syndrome that affects mostly the movement control in PD patients. L-dopa is the main drug that is given as a treatment in PD patients, but its chronic use is linked with the occurrence of additional motor problems, such as motor fluctuations and dyskinesia. Recent data support that Adora2A rs2298393 polymorphism may be a potential risk factor not only for PD, but for Levodopa-Induced Dyskinesia (LID), as well. In this study, we examined 127 Greek patients with PD and 102 healthy controls with Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method, in order to evaluate the association between Adora2A rs2298383 polymorphism and PD in a Greek population. In addition, we explored the association between this particular polymorphism and LID. Our results do not seem to find significant correlation between rs2298393 polymorphism of Adora2A gene with PD or LID.


Parkinson’s Disease, Adora2A gene, Levodopa-Induced Dyskinesia, rs2298383 polymorphism

Full Text:



  • There are currently no refbacks.